Quick answer
What is Semax?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Semax is a peptide, grouped on this site under Neuroactive peptides, and the 12 research records kept here are 7 from studies in rats or mice, 1 from a trial in people and 4 that do not state what kind of study it is.
The literature search returned 207 records. This site keeps 12 of them, which is 5.8 per cent of what came back.
What it is
This site puts it in the Neuroactive peptides group.
Reported in the retrieved records to act on neurotrophin signalling, including BDNF and trkB expression; no single receptor target is established in the retrieved set.[1, 2]
Stated in the titles of the cited 2006 Brain Research and 2001 Neuroscience Letters papers.
What kind of records
A small number of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 1 interventional human trial record among 12 indexed records.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 195 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain research (2006). pmid:16996037
- Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience letters (2001). pmid:11457573